|
Hi Cynthia,
I, too, have wondered about these conflicting results and will be getting my onc's opinion on the subject next time I see her. I'm wondering if, as the HERA trial 'matures', their numbers will come down abit. Or. Could it be because many of the women in HERA had anthracycline-based treatments which have been shown to be beneficial in HER2 cancers? I appreciate that the US trials had adriamycin but the doses in AC are much lower (60mg/m2 X 4 treatments) vs., for example, FEC where the dose for the anthracycline epirubicin is 100mg/m2 X 6 treatments -- well over double the dose of an anthracycline drug!. Anyway. Just a theory. Just what I want to be true. ...I'm hanging on to that 46% and I'm not letting go! : )
Cheers,
/Christine
|